Key Takeaway: Kalaris Therapeutics has reported encouraging results from the expanded cohorts of its Phase 1a SAD trial for TH103, showing positive outcomes in BCVA, OCT, and pharmacokinetics. The findings support the efficacy observed in earlier cohorts. The company continues to enroll participants in the Phase 1b/2 multiple-ascending dose trial, with preliminary data expected in the first half of 2027.
Price reaction · baseline $4.61 (2026-07-16 close) · hit pre-market · 1 other KLRS headline(s) in the window, move may be shared
day 0 close · peak
-5%
Market Sentiment Analysis
POSITIVE FACTORS
Positive results from expanded cohorts in the TH103 trial.
Reinforcement of beneficial findings in BCVA and pharmacokinetics.
Enrollment in the next trial phase is ongoing.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~25 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1
Phase 1 · Viral Infection
Full Press Release Details
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July
Frequently Asked Questions
What were the results of the TH103 Phase 1a trial?
The TH103 Phase 1a trial showed positive results in BCVA, OCT, and pharmacokinetics.
When is preliminary data for the next trial phase expected?
Preliminary data for the Phase 1b/2 trial is expected in the first half of 2027.
What is the focus of the TH103 trial?
The TH103 trial focuses on treating neovascular AMD.
Is enrollment ongoing for the TH103 trial?
Yes, enrollment for the Phase 1b/2 multiple-ascending dose trial is ongoing.